NEW YORK (GenomeWeb News) – Piper Jaffray on Thursday initiated coverage of diagnostics firm Quidel with an Overweight rating, noting the San Diego-based company's move into the molecular diagnostics space.

The investment bank has a $26 price target on Quidel's stock.

Historically, Quidel has depended on its flu and respiratory virus business, and in a research note analyst William Quirk estimated that in 2011 that business made up 48 percent of total revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.